Advertisement

Complications to Medical Treatment

  • Paolo Enrico
  • Ron GoodeyEmail author

Keypoints

  1. 1.

    When medical treatment is blamed, tinnitus may be harder to treat.

     
  2. 2.

    Adverse consequences are better accepted and more easily managed if the patient had been well informed before treatment started and had acknowledged and accepted the risk.

     
  3. 3.

    Ear syringing, suctioning, instrumentation, local anaesthetic injection, grommet insertion, dental treatment, hyperbaric oxygen therapy, and ototoxic ear drops are all relatively minor procedures that may be blamed for tinnitus.

     
  4. 4.

    Major ear operations may cause hearing loss and tinnitus.

     
  5. 5.

    Ototoxic drugs can cause hearing loss and tinnitus after administration systemically, intrathecally, or topically to extensive wounds or burns as well as from use as eardrops.

     
  6. 6.

    Onset of tinnitus is occasionally blamed on radiation therapy, noisy organ imaging, medical equipment accidents, neck manipulation, and general anesthetic.

     
  7. 7.

    Tinnitus can be triggered by procedures on any region of the body when there have been excessive pain and associated anxiety, fear, and anger.

     
  8. 8.

    The medical treatments most commonly accused of causing tinnitus are treatments with drugs. Usually, the tinnitus improves when the drug is withdrawn, provided there is no permanent damage to the cochlea or powerful associated factors.

     
  9. 9.

    Drugs with proven ototoxicity and that also cause tinnitus include aminoglycoside antibiotics, antineoplastic drugs, anti-inflammatory drugs, loop diuretics, antimalarials, and others. The ototoxicity may be synergistic with other agents that damage the inner ear.

     
  10. 10.

    Drugs that are not usually considered ototoxic but are sometimes blamed for causing tinnitus include lidocaine, anticonvulsants, antidepressants, cannabinoids, antihypertensives, beta-adrenergic blocking agents, opioids (buprenorphine), caffeine, and antihistamines. At times, drugs from within most of these groups are also credited with ameliorating tinnitus.

     

Keywords

Tinnitus Complication of treatment Medical misadventure Ototoxicity Pathogenesis Drug-induced tinnitus Therapy-induced tinnitus 

References

  1. 1.
    Coles RA (1996) Compensable tinnitus from causes other than noise, in Proceedings of the Fifth International Tinnitus Seminar: July 12–15, 1995. Portland, Oregon, USA, GE Reich and JA Vernon, Editors. 1996, American Tinnitus Association: Portland, OR. 367–72.Google Scholar
  2. 2.
    Jayarajan V (2003) Tinnitus following ear syringing, in Proceedings of the Seventh International Tinnitus Seminar, Perth, Australia : March 5th–9th, 2002, RB Patuzzi, Editor. 2003, Physiology Dept., University of Western Australia: Perth, Australia. 340–5.Google Scholar
  3. 3.
    Jayarajan V (2003) The effect of significant life events in tinnitus generation, in Proceedings of the Seventh International Tinnitus Seminar, Perth, Australia : March 5th–9th, 2002, RB Patuzzi, Editor. 2003, Physiology Dept., University of Western Australia: Perth, Australia. 238–42.Google Scholar
  4. 4.
    Saunders J (1992) Tinnitus: What is that noise in my head? 1992, Auckland, NZ: Sandalwood Enterprises. 104.Google Scholar
  5. 5.
    Robinson P and A Wright. “Are there links between ear syringing, ear problems and tinnitus?”. Ear Syringing (factsheet) cited; Available from: rnid.org.uk.
  6. 6.
    Tungland OP. Ear Syringing and Tinnitus. Information for Everyone 2005 cited; Available from: www.tinnitus.org.uk.
  7. 7.
    Jang CH, CH Song, SH Kim et al (2004) Influence of suction tube noise on hearing in pediatric patients who received ventilation tube insertion. Chang Gung Med J 27:734–40.PubMedGoogle Scholar
  8. 8.
    Katzke D and G Sesterhenn (1982) Suction-generated noise in the external meatus and sensorineural hearing loss. J Laryngol Otol 96:857–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Pante HJ and P Reuter (1977) Reduction of noise in suction devices. Dtsch Zahnarztl Z 32:490–2.PubMedGoogle Scholar
  10. 10.
    Parkin JL, GS Wood, RD Wood et al (1980) Drill- and suction-generated noise in mastoid surgery. Arch Otolaryngol 106:92–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Spencer MG (1980) Suction tube noise and myringotomy. J Laryngol Otol 94:383–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Ray CD and R Levinson (1992) Noise pollution in the operating room: a hazard to surgeons, personnel, and patients. J Spinal Disord 5:485–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Westcott M (2008) Tonic Tensor Tympani Syndrome – An explanation for everyday sounds causing pain in tinnitus and hyperacusis clients [poster], in IXth International Tinnitus Seminars: Together with the Audiological Seminars: 15–18 June 2008. Göteborg, Sweden. 2008: Göteborg, Sweden. 69.Google Scholar
  14. 14.
    Westcott M (2009) Somatosensory tinnitus and Tonic Tensor Tympani Syndrome (TTTS) [poster abstract], in From clinical practice to basic neuroscience and back: An international conference on tinnitus: Third Tinnitus Research Initiative Meeting, Stresa, Italy. June 24–26, 2009. 2009, TRI: Stresa, Italy. 73.Google Scholar
  15. 15.
    Bingham B, M Hawke and J Halik (1991) The safety and efficacy of Emla cream topical anesthesia for myringotomy and ventilation tube insertion. J Otolaryngol 20:193–5.PubMedGoogle Scholar
  16. 16.
    Langguth B, R Goodey, A Azevedo et al (2007) Consensus for tinnitus patient assessment and treatment outcome measurement: Tinnitus Research Initiative meeting, Regensburg, July 2006. Prog Brain Res 166:525–36.CrossRefPubMedGoogle Scholar
  17. 17.
    Kempf HG, R Roller and L Muhlbradt (1993) Correlation between inner ear disorders and temporomandibular joint diseases. HNO 41:7–10.PubMedGoogle Scholar
  18. 18.
    Brookler KH and MA Hamid (2008) An approach to tinnitus management. Ear Nose Throat J 87:616–21.PubMedGoogle Scholar
  19. 19.
    Bernhardt O, D Gesch, C Schwahn et al (2004) Signs of temporomandibular disorders in tinnitus patients and in a population-based group of volunteers: Results of the Study of Health in Pomerania. J Oral Rehabil 31:311–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Altinoz HC, R Gokbudak, A Bayraktar et al (2001) A pilot study of measurement of the frequency of sounds emitted by high-speed dental air turbines. J Oral Sci 43:189–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Farri A, GC Pecorari, A Enrico et al (2002) Hyperbaric oxygen therapy application in otorhinolaryngology and head and neck surgery: state of the art and review of literature. Acta Otorhinolaryngol Ital 22:227–34.PubMedGoogle Scholar
  22. 22.
    Blanshard J, A Toma, P Bryson et al (1996) Middle ear barotrauma in patients undergoing hyperbaric oxygen therapy. Clin Otolaryngol Allied Sci 21:400–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Fiesseler FW, ME Silverman, RL Riggs et al (2006) Indication for hyperbaric oxygen treatment as a predictor of tympanostomy tube placement. Undersea Hyperb Med 33:231–5.PubMedGoogle Scholar
  24. 24.
    Abello P, JB Vinas and J Vega (1998) Topical ototoxicity: review over a 6-year period. Acta Otorrinolaringol Esp 49:353–6.PubMedGoogle Scholar
  25. 25.
    Mahadevan M, DA Wabnitz, DL McIntosh et al (2008) Survey on the use of ototopical medications by New Zealand otolaryngologist/head and neck surgeons. N Z Med J 121:U2898.PubMedGoogle Scholar
  26. 26.
    Daniel SJ and R Munguia (2008) Ototoxicity of topical ciprofloxacin/dexamethasone otic suspension in a chinchilla animal model. Otolaryngol Head Neck Surg 139:840–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Ikiz AO, B Serbetcioglu, EA Guneri et al (1998) Investigation of topical ciprofloxacin ototoxicity in guinea pigs. Acta Otolaryngol 118:808–12.CrossRefPubMedGoogle Scholar
  28. 28.
    Wai TK and MC Tong (2003) A benefit-risk assessment of ofloxacin otic solution in ear infection. Drug Saf 26:405–20.CrossRefPubMedGoogle Scholar
  29. 29.
    Marshall NE, KV Ballman, JC Michalak et al (2006) Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. J Neurooncol 77:315–20.CrossRefPubMedGoogle Scholar
  30. 30.
    Vernon J, L Press and T McLaughlin (1996) Magnetic resonance imaging and tinnitus. Otolaryngol Head Neck Surg 115:587–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen B, Y Wang, D Wang et al (2004) Evaluation of safety on the noise of drills in the tympanoplasty. Lin Chuang Er Bi Yan Hou Ke Za Zhi 18:4–5.PubMedGoogle Scholar
  32. 32.
    Kraft CN, R Conrad, M Vahlensieck et al (2001) Non-cerebrovascular complication in chirotherapy manipulation of the cervical vertebrae. Z Orthop Ihre Grenzgeb 139:8–11.CrossRefPubMedGoogle Scholar
  33. 33.
    Arslan E, E Orzan and R Santarelli (1999) Global problem of drug-induced hearing loss. Ann N Y Acad Sci 884:1–14.PubMedGoogle Scholar
  34. 34.
    Cianfrone G, M Pace, R Turchetta et al (2005) Guida ed aggiornamento sui farmaci ototossici, tinnitogeni e vertigogeni. Acta Otorhinolaryngol Ital 25:28.Google Scholar
  35. 35.
    Yorgason JG, JN Fayad and F Kalinec (2006) Understanding drug ototoxicity: molecular insights for prevention and clinical management. Expert Opin Drug Saf 5:383–99.CrossRefPubMedGoogle Scholar
  36. 36.
    Brunton LL, JS Lazo and KL Parker (2005) Goodman and Gilman’s The Pharmacological Basis of Therapeutics Laurence Brunton, Editors. McGraw-Hill, New York.Google Scholar
  37. 37.
    Durante-Mangoni E, A Grammatikos, R Utili et al (2009) Do we still need the aminoglycosides? Int J Antimicrob Agents 33:201–5.CrossRefPubMedGoogle Scholar
  38. 38.
    East JE, JE Foweraker and FD Murgatroyd (2005) Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin. Heart 91:e32.CrossRefPubMedGoogle Scholar
  39. 39.
    Rybak LP and V Ramkumar (2007) Ototoxicity. Kidney Int 72:931–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Bitner-Glindzicz M and S Rahman (2007) Ototoxicity caused by aminoglycosides. BMJ 335:784–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Selimoglu E (2007) Aminoglycoside-induced ototoxicity. Curr Pharm Des 13:119–26.CrossRefPubMedGoogle Scholar
  42. 42.
    Chen Y, WG Huang, DJ Zha et al (2007) Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 226:178–82.CrossRefPubMedGoogle Scholar
  43. 43.
    Perletti G, A Vral, MC Patrosso et al (2008) Prevention and modulation of aminoglycoside ototoxicity (Review). Mol Med Rep 1:10.Google Scholar
  44. 44.
    Sergi B, AR Fetoni, A Ferraresi et al (2004) The role of antioxidants in protection from ototoxic drugs. Acta Otolaryngol Suppl 552:42–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Rizzi MD and K Hirose (2007) Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 15:352–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Bates DE, SJ Beaumont and BW Baylis (2002) Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother 36:446–51.CrossRefPubMedGoogle Scholar
  47. 47.
    Mir O, S Ropert and F Goldwasser (2009) Cisplatin as a cornerstone of modern chemotherapy. Lancet Oncol 10:304.CrossRefPubMedGoogle Scholar
  48. 48.
    Kyrtopoulos SA, LM Anderson, SK Chhabra et al (1997) DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. Cancer Detect Prev 21:391–405.PubMedGoogle Scholar
  49. 49.
    Shamkhani H, LM Anderson, CE Henderson et al (1994) DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod Toxicol 8:207–16.CrossRefPubMedGoogle Scholar
  50. 50.
    Hartmann JT and HP Lipp (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4:889–901.CrossRefPubMedGoogle Scholar
  51. 51.
    Mir O, P Berveiller, S Ropert et al (2008) Use of platinum derivatives during pregnancy. Cancer 113:3069–74.CrossRefPubMedGoogle Scholar
  52. 52.
    Rybak LP, CA Whitworth, D Mukherjea et al (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226:157–67.CrossRefPubMedGoogle Scholar
  53. 53.
    Oldenburg J, SD Fossa and T Ikdahl (2008) Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 9:1521–30.CrossRefPubMedGoogle Scholar
  54. 54.
    Riedemann L, C Lanvers, D Deuster et al (2008) Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8:23–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Huang RS, S Duan, SJ Shukla et al (2007) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 81:427–37.CrossRefPubMedGoogle Scholar
  56. 56.
    Knoll C, RJ Smith, C Shores et al (2006) Hearing genes and cisplatin deafness: a pilot study. Laryngoscope 116:72–4.CrossRefPubMedGoogle Scholar
  57. 57.
    Rademaker-Lakhai JM, M Crul, L Zuur et al (2006) Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24:918–24.CrossRefPubMedGoogle Scholar
  58. 58.
    Zuur CL, YJ Simis, RS Verkaik et al (2008) Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol 89:38–43.CrossRefPubMedGoogle Scholar
  59. 59.
    Fetoni AR, B Sergi, A Ferraresi et al (2004) Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol 124:421–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Thomas Dickey D, LL Muldoon, DF Kraemer et al (2004) Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193:25–30.CrossRefPubMedGoogle Scholar
  61. 61.
    Bertolini P, M Lassalle, G Mercier et al (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649–55.CrossRefPubMedGoogle Scholar
  62. 62.
    Coradini PP, L Cigana, SG Selistre et al (2007) Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 29:355–60.CrossRefPubMedGoogle Scholar
  63. 63.
    Helt-Cameron J and PJ Allen (2009) Cisplatin ototoxicity in children: implications for primary care providers. Pediatr Nurs 35:121–7.PubMedGoogle Scholar
  64. 64.
    Knight KR, DF Kraemer and EA Neuwelt (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–96.CrossRefPubMedGoogle Scholar
  65. 65.
    Li Y, RB Womer and JH Silber (2004) Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 40:2445–51.CrossRefPubMedGoogle Scholar
  66. 66.
    Dhooge I, C Dhooge, S Geukens et al (2006) Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol 45:337–43.CrossRefPubMedGoogle Scholar
  67. 67.
    Fisher MJ, BJ Lange, MN Needle et al (2004) Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 43:780–4.CrossRefPubMedGoogle Scholar
  68. 68.
    Fouladi M, M Chintagumpala, D Ashley et al (2008) Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26:3749–55.CrossRefPubMedGoogle Scholar
  69. 69.
    Freyer DR, L Sung and GH Reaman (2009) Prevention of hearing loss in children receiving cisplatin chemotherapy. J Clin Oncol 27:317–8; author reply 8–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Katzenstein HM, KW Chang, M Krailo et al (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115:5828–35.CrossRefPubMedGoogle Scholar
  71. 71.
    Marina N, KW Chang, M Malogolowkin et al (2005) Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children’s Oncology Group study. Cancer 104:841–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Sastry J and SJ Kellie (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22:441–5.CrossRefPubMedGoogle Scholar
  73. 73.
    World Health Organization (2008) World Malaria Report 2008.Google Scholar
  74. 74.
    Centers for Disease Control and Prevention (2008) Malaria Surveillance – United States, 2007. MMWR 58:16.Google Scholar
  75. 75.
    Ashley E, R McGready, S Proux et al (2006) Malaria. Travel Med Infect Dis 4:159–73.CrossRefPubMedGoogle Scholar
  76. 76.
    Berman J (2004) Toxicity of commonly-used antimalarial drugs. Travel Med Infect Dis 2:171–84.CrossRefPubMedGoogle Scholar
  77. 77.
    Centers for Disease Control and Prevention (2009) The Pre-Travel Consultation – Malaria, in Health Information for International Travel 2010. 2009.Google Scholar
  78. 78.
    Gkrania-Klotsas E and AM Lever (2007) An update on malaria prevention, diagnosis and treatment for the returning traveller. Blood Rev 21:73–87.CrossRefPubMedGoogle Scholar
  79. 79.
    Lalloo DG, D Shingadia, G Pasvol et al (2007) UK malaria treatment guidelines. J Infect 54:111–21.CrossRefPubMedGoogle Scholar
  80. 80.
    Sullivan DJ, Jr., IY Gluzman, DG Russell et al (1996) On the molecular mechanism of chloroquine’s antimalarial action. Proc Natl Acad Sci U S A 93:11865–70.CrossRefPubMedGoogle Scholar
  81. 81.
    Huston M and M Levinson (2006) Are one or two dangerous? Quinine and quinidine exposure in toddlers. J Emerg Med 31:395–401.CrossRefPubMedGoogle Scholar
  82. 82.
    Taylor S (2004) Quinine intoxications: a continuing problem. Br J Clin Pharmacol 57:817; author reply.CrossRefPubMedGoogle Scholar
  83. 83.
    Nosten F, R McGready, U d’Alessandro et al (2006) Antimalarial drugs in pregnancy: a review. Curr Drug Saf 1:1–15.CrossRefPubMedGoogle Scholar
  84. 84.
    Ostensen M and M Motta (2007) Therapy insight: the use of antirheumatic drugs during nursing. Nat Clin Pract Rheumatol 3:400–6.CrossRefPubMedGoogle Scholar
  85. 85.
    Ward SA, EJ Sevene, IM Hastings et al (2007) Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7:136–44.CrossRefPubMedGoogle Scholar
  86. 86.
    Alvan G, KK Karlsson, U Hellgren et al (1991) Hearing impairment related to plasma quinine concentration in healthy volunteers. Br J Clin Pharmacol 31:409–12.CrossRefPubMedGoogle Scholar
  87. 87.
    Jastreboff PJ, JF Brennan and CT Sasaki (1991) Quinine-induced tinnitus in rats. Arch Otolaryngol Head Neck Surg 117:1162–6.CrossRefPubMedGoogle Scholar
  88. 88.
    Paintaud G, G Alvan, E Berninger et al (1994) The concentration-effect relationship of quinine-induced hearing impairment. Clin Pharmacol Ther 55:317–23.CrossRefPubMedGoogle Scholar
  89. 89.
    Bortoli R and M Santiago (2007) Chloroquine ototoxicity. Clin Rheumatol 26:1809–10.CrossRefPubMedGoogle Scholar
  90. 90.
    Gurkov R, T Eshetu, IB Miranda et al (2008) Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J 7:179.CrossRefPubMedGoogle Scholar
  91. 91.
    Hadi U, N Nuwayhid and AS Hasbini (1996) Chloroquine ototoxicity: an idiosyncratic phenomenon. Otolaryngol Head Neck Surg 114:491–3.CrossRefPubMedGoogle Scholar
  92. 92.
    Jarboe JK and R Hallworth (1999) The effect of quinine on outer hair cell shape, compliance and force. Hear Res 132:43–50.CrossRefPubMedGoogle Scholar
  93. 93.
    Karlsson KK and A Flock (1990) Quinine causes isolated outer hair cells to change length. Neurosci Lett 116:101–5.CrossRefPubMedGoogle Scholar
  94. 94.
    Karlsson KK, M Ulfendahl, SM Khanna et al (1991) The effects of quinine on the cochlear mechanics in the isolated temporal bone preparation. Hear Res 53:95–100.CrossRefPubMedGoogle Scholar
  95. 95.
    Zheng J, T Ren, A Parthasarathi et al (2001) Quinine-induced alterations of electrically evoked otoacoustic emissions and cochlear potentials in guinea pigs. Hear Res 154:124–34.CrossRefPubMedGoogle Scholar
  96. 96.
    Jung TT, CK Rhee, CS Lee et al (1993) Ototoxicity of salicylate, nonsteroidal antiinflammatory drugs, and quinine. Otolaryngol Clin North Am 26:791–810.PubMedGoogle Scholar
  97. 97.
    Shine NP and H Coates (2005) Systemic ototoxicity: a review. East Afr Med J 82:536–9.PubMedGoogle Scholar
  98. 98.
    Coutinho MB and I Duarte (2002) Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis. Int J Pediatr Otorhinolaryngol 62:53–7.CrossRefPubMedGoogle Scholar
  99. 99.
    Taylor WR and NJ White (2004) Antimalarial drug toxicity: a review. Drug Saf 27:25–61.CrossRefPubMedGoogle Scholar
  100. 100.
    Karbwang J, KN Bangchang, A Thanavibul et al (1994) Quinine toxicity when given with doxycycline and mefloquine. Southeast Asian J Trop Med Public Health 25:397–400.PubMedGoogle Scholar
  101. 101.
    AlKadi HO (2007) Antimalarial drug toxicity: a review. Chemotherapy 53:385–91.CrossRefPubMedGoogle Scholar
  102. 102.
    Amann R and BA Peskar (2002) Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 447:1–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Yasuda O, Y Takemura, H Kawamoto et al (2008) Aspirin: recent developments. Cell Mol Life Sci 65:354–8.CrossRefPubMedGoogle Scholar
  104. 104.
  105. 105.
    Bjorklund L, MA Wallander, S Johansson et al (2009) Aspirin in cardiology – benefits and risks. Int J Clin Pract 63:468–77.CrossRefPubMedGoogle Scholar
  106. 106.
    Wolff T, T Miller and S Ko (2009) Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150:405–10.PubMedGoogle Scholar
  107. 107.
    Cuzick J, F Otto, JA Baron et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–7.CrossRefPubMedGoogle Scholar
  108. 108.
    Elwood PC, AM Gallagher, GG Duthie et al (2009) Aspirin, salicylates, and cancer. Lancet 373:1301–9.CrossRefPubMedGoogle Scholar
  109. 109.
    O’Kane P, L Xie, Z Liu et al (2009) Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res 83:123–30.CrossRefPubMedGoogle Scholar
  110. 110.
    Ressel G (2002) AAP updates statement for transfer of drugs and other chemicals into breast milk. American Academy of Pediatrics. Am Fam Physician 65:979–80.PubMedGoogle Scholar
  111. 111.
    Marchese-Ragona R, G Marioni, P Marson et al (2008) The discovery of salicylate ototoxicity. Audiol Neurootol 13:34–6.CrossRefPubMedGoogle Scholar
  112. 112.
    Cazals Y (2000) Auditory sensori-neural alterations induced by salicylate. Prog Neurobiol 62:583–631.CrossRefPubMedGoogle Scholar
  113. 113.
    Koren G (2009) Hearing loss in a woman on aspirin: the silent pharmacokinetic parameter. Ther Drug Monit 31:1–2.CrossRefPubMedGoogle Scholar
  114. 114.
    Ermilov SA, DR Murdock, D El-Daye et al (2005) Effects of salicylate on plasma membrane mechanics. J Neurophysiol 94:2105–10.CrossRefPubMedGoogle Scholar
  115. 115.
    Frolenkov GI (2006) Regulation of electromotility in the cochlear outer hair cell. J Physiol 576:43–8.CrossRefPubMedGoogle Scholar
  116. 116.
    Puel JL (2007) Cochlear NMDA receptor blockade prevents salicylate-induced tinnitus. B-ENT 3 Suppl 7:19–22.PubMedGoogle Scholar
  117. 117.
    Puel JL and MJ Guitton (2007) Salicylate-induced tinnitus: molecular mechanisms and modulation by anxiety. Prog Brain Res 166:141–6.CrossRefPubMedGoogle Scholar
  118. 118.
    Sun W, J Lu, D Stolzberg et al (2009) Salicylate increases the gain of the central auditory system. Neuroscience 159:325–34.CrossRefPubMedGoogle Scholar
  119. 119.
    Hyppolito MA, JA de Oliveira and M Rossato (2006) Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol 263:798–803.CrossRefPubMedGoogle Scholar
  120. 120.
    Minami SB, SH Sha and J Schacht (2004) Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res 198:137–43.CrossRefPubMedGoogle Scholar
  121. 121.
    Dargan PI, CI Wallace and AL Jones (2002) An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J 19:206–9.CrossRefPubMedGoogle Scholar
  122. 122.
    Samlan SR, MT Jordan, SB Chan et al (2008) Tinnitus as a measure of salicylate toxicity in the overdose setting. West J Emerg Med 9:146–9.PubMedGoogle Scholar
  123. 123.
    Michael JB and MD Sztajnkrycer (2004) Deadly pediatric poisons: nine common agents that kill at low doses. Emerg Med Clin North Am 22:1019–50.CrossRefPubMedGoogle Scholar
  124. 124.
    Baxter AJ, R Mrvos and EP Krenzelok (2003) Salicylism and herbal medicine. Am J Emerg Med 21:448–9.CrossRefPubMedGoogle Scholar
  125. 125.
    Bell AJ and G Duggin (2002) Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emerg Med (Fremantle) 14:188–90.CrossRefGoogle Scholar
  126. 126.
    Hofman M, JE Diaz and C Martella (1998) Oil of wintergreen overdose. Ann Emerg Med 31:793–4.CrossRefPubMedGoogle Scholar
  127. 127.
    Baguley DM, S Jones, I Wilkins et al (2005) The inhibitory effect of intravenous lidocaine infusion on tinnitus after translabyrinthine removal of vestibular schwannoma: a double-blind, placebo-controlled, crossover study. Otol Neurotol 26:169–76.CrossRefPubMedGoogle Scholar
  128. 128.
    Haginomori S, K Makimoto, M Araki et al (1995) Effect of lidocaine injection of EOAE in patients with tinnitus. Acta Otolaryngol 115:488–92.CrossRefPubMedGoogle Scholar
  129. 129.
    Otsuka K, JL Pulec and M Suzuki (2003) Assessment of intravenous lidocaine for the treatment of subjective tinnitus. Ear Nose Throat J 82:781–4.PubMedGoogle Scholar
  130. 130.
    Sanchez TG, AP Balbani, RS Bittar et al (1999) Lidocaine test in patients with tinnitus: rationale of accomplishment and relation to the treatment with carbamazepine. Auris Nasus Larynx 26:411–7.CrossRefPubMedGoogle Scholar
  131. 131.
    Kalcioglu MT, T Bayindir, T Erdem et al (2005) Objective evaluation of the effects of intravenous lidocaine on tinnitus. Hear Res 199:81–8.CrossRefPubMedGoogle Scholar
  132. 132.
    Butterworth JFt and GR Strichartz (1990) Molecular mechanisms of local anesthesia: a review. Anesthesiology 72:711–34.CrossRefPubMedGoogle Scholar
  133. 133.
    Chevrier P, K Vijayaragavan and M Chahine (2004) Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol 142:576–84.CrossRefPubMedGoogle Scholar
  134. 134.
    Scholz A (2002) Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth 89:52–61.CrossRefPubMedGoogle Scholar
  135. 135.
    Trellakis S, D Benzenberg, BW Urban et al (2006) Differential lidocaine sensitivity of human voltage-gated potassium channels relevant to the auditory system. Otol Neurotol 27:117–23.CrossRefPubMedGoogle Scholar
  136. 136.
    Bortone DS, K Mitchell and PB Manis (2006) Developmental time course of potassium channel expression in the rat cochlear nucleus. Hear Res 211:114–25.CrossRefPubMedGoogle Scholar
  137. 137.
    Grigg JJ, HM Brew and BL Tempel (2000) Differential expression of voltage-gated potassium channel genes in auditory nuclei of the mouse brainstem. Hear Res 140:77–90.CrossRefPubMedGoogle Scholar
  138. 138.
    Holt AG, M Asako, RK Duncan et al (2006) Deafness associated changes in expression of two-pore domain potassium channels in the rat cochlear nucleus. Hear Res 216-217:146–53.CrossRefPubMedGoogle Scholar
  139. 139.
    Kaczmarek LK, A Bhattacharjee, R Desai et al (2005) Regulation of the timing of MNTB neurons by short-term and long-term modulation of potassium channels. Hear Res 206:133–45.CrossRefPubMedGoogle Scholar
  140. 140.
    Shiomi Y, K Funabiki, Y Naito et al (1997) The effect of intravenous lidocaine injection on hearing thresholds. Auris Nasus Larynx 24:351–6.CrossRefPubMedGoogle Scholar
  141. 141.
    Ruth RA, TJ Gal, CA DiFazio et al (1985) Brain-stem auditory-evoked potentials during lidocaine infusion in humans. Arch Otolaryngol 111:799–802.CrossRefPubMedGoogle Scholar
  142. 142.
    Giraud AL, S Chery-Croze, G Fischer et al (1999) A selective imaging of tinnitus. Neuroreport 10:1–5.CrossRefPubMedGoogle Scholar
  143. 143.
    Staffen W, E Biesinger, E Trinka et al (1999) The effect of lidocaine on chronic tinnitus: a quantitative cerebral perfusion study. Audiology 38:53–7.CrossRefPubMedGoogle Scholar
  144. 144.
    Reyes SA, RJ Salvi, RF Burkard et al (2002) Brain imaging of the effects of lidocaine on tinnitus. Hear Res 171:43–50.CrossRefPubMedGoogle Scholar
  145. 145.
    Ettinger AB and CE Argoff (2007) Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 4:75–83.CrossRefPubMedGoogle Scholar
  146. 146.
    Rogawski MA and W Loscher (2004) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10:685–92.CrossRefPubMedGoogle Scholar
  147. 147.
    Dobie RA (1999) A review of randomized clinical trials in tinnitus. Laryngoscope 109:1202–11.CrossRefPubMedGoogle Scholar
  148. 148.
    Robinson SK, ES Viirre and MB Stein (2007) Antidepressant therapy in tinnitus. Hear Res 226:221–31.CrossRefPubMedGoogle Scholar
  149. 149.
    McKenna L, RS Hallam and R Hinchcliffe (1991) The prevalence of psychological disturbance in neurotology outpatients. Clin Otolaryngol Allied Sci 16:452–6.CrossRefPubMedGoogle Scholar
  150. 150.
    Zoger S, J Svedlund and KM Holgers (2006) Relationship between tinnitus severity and psychiatric disorders. Psychosomatics 47:282–8.CrossRefPubMedGoogle Scholar
  151. 151.
    Mico JA, D Ardid, E Berrocoso et al (2006) Antidepressants and pain. Trends Pharmacol Sci 27:348–54.CrossRefPubMedGoogle Scholar
  152. 152.
    Reisner L (2003) Antidepressants for chronic neuropathic pain. Curr Pain Headache Rep 7:24–33.CrossRefPubMedGoogle Scholar
  153. 153.
    Møller AR (1997) Similarities between chronic pain and tinnitus. Am J Otol 18:577–85.PubMedGoogle Scholar
  154. 154.
    Møller AR (2000) Similarities between severe tinnitus and chronic pain. J Am Acad Audiol 11:115–24.PubMedGoogle Scholar
  155. 155.
    Feder R (1990) Tinnitus associated with amitriptyline. J Clin Psychiatry 51:85–6.PubMedGoogle Scholar
  156. 156.
    Koshes RJ (1992) Use of amitriptyline in a patient with tinnitus. Psychosomatics 33:341–3.CrossRefPubMedGoogle Scholar
  157. 157.
    Mendis D and M Johnston (2008) An unusual case of prolonged tinnitus following low-dose amitriptyline. J Psychopharmacol 22:574–5.CrossRefPubMedGoogle Scholar
  158. 158.
    Ahmad S (1995) Venlafaxine and severe tinnitus. Am Fam Physician 51:1830.PubMedGoogle Scholar
  159. 159.
    Farah A and TE Lauer (1996) Possible venlafaxine withdrawal syndrome. Am J Psychiatry 153:576.PubMedGoogle Scholar
  160. 160.
    Leiter FL, AA Nierenberg, KM Sanders et al (1995) Discontinuation reactions following sertraline. Biol Psychiatry 38:694–5.CrossRefPubMedGoogle Scholar
  161. 161.
    Baldo P, C Doree, R Lazzarini et al (2006) Antidepressants for patients with tinnitus. Cochrane Database Syst Rev 4:CD003853.PubMedGoogle Scholar
  162. 162.
    Robinson SK, ES Viirre, KA Bailey et al (2005) Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 67:981–8.CrossRefPubMedGoogle Scholar
  163. 163.
    Kisely S and LA Campbell (2008) Use of smoking cessation therapies in individuals with psychiatric illness : an update for prescribers. CNS Drugs 22:263–73.CrossRefPubMedGoogle Scholar
  164. 164.
    Siu EC and RF Tyndale (2007) Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 47:541–64.CrossRefPubMedGoogle Scholar
  165. 165.
    Humma LM and MP Swims (1999) Bupropion mimics a transient ischemic attack. Ann Pharmacother 33:305–7.CrossRefPubMedGoogle Scholar
  166. 166.
    Settle EC, Jr. (1991) Tinnitus related to bupropion treatment. J Clin Psychiatry 52:352.PubMedGoogle Scholar
  167. 167.
    Ashton JC and ED Milligan (2008) Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Investig Drugs 9:65–75.PubMedGoogle Scholar
  168. 168.
    Ben Amar M (2006) Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105:1–25.CrossRefPubMedGoogle Scholar
  169. 169.
    Di Marzo V and LD Petrocellis (2006) Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 57:553–74.CrossRefPubMedGoogle Scholar
  170. 170.
    Dalton GD, CE Bass, C Van Horn et al (2009) Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 8:422–31CrossRefPubMedGoogle Scholar
  171. 171.
    Demuth DG and A Molleman (2006) Cannabinoid signalling. Life Sci 78:549–63.CrossRefPubMedGoogle Scholar
  172. 172.
    Howlett AC (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68–69:619–31.CrossRefPubMedGoogle Scholar
  173. 173.
    Mouslech Z and V Valla (2009) Endocannabinoid system: an overview of its potential in current medical practice. Neuro Endocrinol Lett 30:153–79.PubMedGoogle Scholar
  174. 174.
    Aggarwal SK, GT Carter, MD Sullivan et al (2009) Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 5:153–68.PubMedGoogle Scholar
  175. 175.
    Cohen PJ (2009) Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two. J Pain Palliat Care Pharmacother 23:120–40.CrossRefPubMedGoogle Scholar
  176. 176.
    Zheng Y, JH Baek, PF Smith et al (2007) Cannabinoid receptor down-regulation in the ventral cochlear nucleus in a salicylate model of tinnitus. Hear Res 228:105–11.CrossRefPubMedGoogle Scholar
  177. 177.
    Raby WN, PA Modica, RJ Wolintz et al (2006) Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: a case report. J Ocul Pharmacol Ther 22:68–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Section of Otolaryngology, Department of SurgeryUniversity of AucklandAucklandNew Zealand

Personalised recommendations